Sequencing Immunotherapy in the Third-line and Beyond Setting for FL

Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.

Related Keywords

Peter Martin , ,Recent Updates ,Follicular Lymphoma ,Mantle Cell Lymphoma ,Beyond Setting ,Fl ,Patient Preference ,Cellular Therapy ,Clinical Factor ,Real World Data ,Quality Of Life ,Bispecific Antibody ,Bendamustine ,Cart Cell ,Retrospective ,Immunotherapy ,Sequencing Therapy ,Cart Cell Therapy ,